South China Morning Post
Shares of METiS TechBio surged on their Hong Kong debut on Wednesday as the AI-driven drug design start-up’s initial public offering drew strong demand from investors amid buoyant sentiment for AI-related stocks in the city. Artificial intelligence has shortened drug development from years to just 18 months, said Lai Tsai-Ta, co-founder and CEO of METiS TechBio, who obtained a PhD from the Massachusetts Institute of Technology in the US. “We see ourselves like a SpaceX-style company,” he said....
Go to News Site